Home›Stocks›HUMA

HUMA — structural market context

Humacyte, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

HUMA short interest & days to cover

SHARES SHORT
31.5M
% OF FLOAT
—
DAYS TO COVER
6.9
CHANGE VS PRIOR
-2.5%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-07-31 (20d ago)

HUMA fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-07-30 · 21d3K$0.62
2026-07-29 · 22d44K$0.63
2026-07-28 · 23d45$0.67

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

HUMA insider buying and selling (Form 4)

Last 12 months, open-market only: 1 purchase · 0 sales

InsiderTypeSharesValueFiled
Jones Keith Anthony · directorBuy (P)30K$18K2026-08-19

SEC Form 4 filings, open-market purchases and sales only (codes P and S); grants and option exercises excluded. Attributed public records.

Frequently asked questions

Are insiders buying HUMA?
In the last 12 months of SEC Form 4 filings, HUMA recorded 1 open-market insider purchase and 0 open-market sales (codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
Is this page telling me to buy or sell HUMA?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerAnalyst Accuracy trackerThe platform

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.